FDA Approves Truseltiq (infigratinib) for the Treatment of Cholangiocarcinoma
FDA Approves Truseltiq (infigratinib) for the Treatment of Cholangiocarcinoma PALO ALTO, Calif. and LUGANO, Switzerland, May 28, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has approved Truseltiq (infigratinib) under the accelerated approval program for… Read More »